These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 9313603

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S, Kobrin I, Abernethy DR, Levine BS, Reif MC, Shepherd AM.
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [Abstract] [Full Text] [Related]

  • 3. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect.
    Carney S, Wing L, Ribeiro A, Kallwellis R, Zimlichman R, Viskoper RJ, Mion D, Kobrin I.
    J Hum Hypertens; 1997 Jul; 11(7):459-66. PubMed ID: 9283064
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
    Karch FE, Pordy R, Benz JR, Carr A, Lunde NM, Marbury T, Tarro JN.
    Clin Ther; 1997 Jul; 19(6):1368-78. PubMed ID: 9444446
    [Abstract] [Full Text] [Related]

  • 7. Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD. Mibefradil Hypertension Study Group.
    Bittar N.
    Clin Ther; 1997 Jul; 19(5):954-62. PubMed ID: 9385483
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension.
    Chung O, Hinder M, Sharma AM, Bönner G, Middeke M, Platon J, Unger T.
    Fundam Clin Pharmacol; 2000 Jul; 14(1):31-41. PubMed ID: 10681072
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME, Kelly MW.
    Pharmacotherapy; 1998 Jul; 18(3):463-85. PubMed ID: 9620098
    [Abstract] [Full Text] [Related]

  • 12. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I, Charlon V, Lindberg E, Pordy R.
    Am J Cardiol; 1997 Aug 21; 80(4B):40C-46C. PubMed ID: 9286853
    [Abstract] [Full Text] [Related]

  • 13. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
    Woittiez AJ, Huysmans FT, Bailey R, Robson RA, Mion Júnior D, Villa G, Kobrin I.
    Clin Nephrol; 1998 Mar 21; 49(3):160-6. PubMed ID: 9543597
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I.
    Am Heart J; 1995 Oct 21; 130(4):748-57. PubMed ID: 7572582
    [Abstract] [Full Text] [Related]

  • 16. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S, van der Wall EE, Emanuelsson H, Kobrin I.
    J Am Coll Cardiol; 1996 Feb 21; 27(2):317-22. PubMed ID: 8557900
    [Abstract] [Full Text] [Related]

  • 17. A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
    Viskoper RJ, Bernink PJ, Schelling A, Ribeiro AB, Kantola IM, Wilkins MR, Kobrin I.
    J Hum Hypertens; 1997 Jun 21; 11(6):387-93. PubMed ID: 9249234
    [Abstract] [Full Text] [Related]

  • 18. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA, Bernink PJ, van der Wall EE, van Velhuisen DJ, Braun S, Kobrin I.
    Clin Ther; 1996 Jun 21; 18(6):1191-206. PubMed ID: 9001836
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.